{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:10:49Z","timestamp":1790028649633,"version":"4.0.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014869","name":"BTG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014869","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019628","name":"BioPorto A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004702","name":"Baxter International Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004702","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer Global Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.kint.2026.01.037","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:10:24Z","timestamp":1774311024000},"page":"1114-1124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Conventional cytotoxic chemotherapy\u2013associated nephrotoxicity: consensus report of the 34th Acute Disease Quality Initiative (ADQI) Workgroup"],"prefix":"10.1016","volume":"109","author":[{"given":"Paolo","family":"Lentini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Whitman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Jaimes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0617-5309","authenticated-orcid":false,"given":"Lui","family":"Forni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cosmai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Perazella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Ballen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"DeMauro Renaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Fenoglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Floris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas E.","family":"Gladstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilya G.","family":"Glezerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart L.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra M.","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenar D.","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Karam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijat","family":"Kitchlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J.","family":"Landau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheron","family":"Latcha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Leaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Ma\u0142yszko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Markowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoka","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies","family":"Ostermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonello","family":"Pani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Rashidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Roccatello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Ronco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell H.","family":"Rosner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Sharon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Sprangers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladim\u00edr","family":"Tesa\u0159","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f4nica","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimda","family":"Wanchoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biruh T.","family":"Workeneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Zepeda-Orozco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2026.01.037_bib1","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1053\/j.ackd.2021.08.001","article-title":"Conventional chemotherapy nephrotoxicity","volume":"28","author":"Gupta","year":"2021","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.kint.2026.01.037_bib2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/039139880803100202","article-title":"Acute dialysis quality initiative (ADQI): methodology","volume":"31","author":"Kellum","year":"2008","journal-title":"Int J Artif Organs"},{"key":"10.1016\/j.kint.2026.01.037_bib3","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1124\/jpet.124.002287","article-title":"understanding cisplatin pharmacokinetics and toxicodynamics to predict and prevent kidney injury","volume":"391","author":"Thompson","year":"2024","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.kint.2026.01.037_bib4","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/967826","article-title":"Pathophysiology of cisplatin-induced acute kidney injury","volume":"2014","author":"Ozkok","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.kint.2026.01.037_bib5","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.3390\/ijms20123011","article-title":"Recent advances in models, mechanisms, biomarkers, and interventions in cisplatin-induced acute kidney injury","volume":"20","author":"Holditch","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.kint.2026.01.037_bib6","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.47739\/pharmacology1184","article-title":"A pharmacokinetic\/toxicodynamic model of cisplatin nephrotoxicity using the kidney injury molecule-1 biomarker","volume":"12","author":"Thompson","year":"2024","journal-title":"J Pharmacol Clin Toxicol"},{"key":"10.1016\/j.kint.2026.01.037_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-077169","article-title":"Derivation and external validation of a simple risk score for predicting severe acute kidney injury after intravenous cisplatin: cohort study","volume":"384","author":"Gupta","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.kint.2026.01.037_bib8","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1001\/jamaoncol.2025.2590","article-title":"Predicting chronic kidney disease after cisplatin treatment using population-level data","volume":"11","author":"Grant","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.kint.2026.01.037_bib9","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s40265-019-01182-1","article-title":"Prevention of cisplatin-induced acute kidney injury: a systematic review and meta-analysis","volume":"79","author":"Hamroun","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.kint.2026.01.037_bib10","doi-asserted-by":"crossref","first-page":"F1041","DOI":"10.1152\/ajprenal.00512.2019","article-title":"Canagliflozin reduces cisplatin uptake and activates Akt to protect against cisplatin-induced nephrotoxicity","volume":"318","author":"Song","year":"2020","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2026.01.037_bib11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/ndt\/gfae233","article-title":"Effect of mannitol on cisplatin-associated acute kidney injury: a target trial emulation","volume":"40","author":"Gupta","year":"2025","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1016\/j.kint.2026.01.037_bib12","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2215\/CJN.08070715","article-title":"Long-term renal outcomes after cisplatin treatment","volume":"11","author":"Latcha","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.01.037_bib13","first-page":"1636","article-title":"Risk factors for nephrotoxicity after ifosfamide treatment in children","volume":"82","author":"Skinner","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.kint.2026.01.037_bib14","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.ejca.2012.03.009","article-title":"Long-term renal toxicity of ifosfamide in adult patients\u20145-year data","volume":"48","author":"Farry","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.kint.2026.01.037_bib15","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/ckj\/sfz183","article-title":"Ifosfamide nephrotoxicity in adult patients","volume":"13","author":"Ensergueix","year":"2020","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2026.01.037_bib16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2133\/dmpk.DMPK-13-RV-119","article-title":"Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy","volume":"29","author":"Inoue","year":"2014","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.kint.2026.01.037_bib17","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.3109\/10428194.2013.840780","article-title":"High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis","volume":"55","author":"May","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.kint.2026.01.037_bib18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/phar.2889","article-title":"Development and validation of a model to predict acute kidney injury following high-dose methotrexate in patients with lymphoma","volume":"44","author":"Rice","year":"2024","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.kint.2026.01.037_bib19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/2399369319827305","article-title":"High-flux hemodialysis versus glucarpidase for methotrexate-associated acute kidney injury: what\u2019s best?","volume":"3","author":"Kitchlu","year":"2019","journal-title":"J Onco-Nephrol"},{"key":"10.1016\/j.kint.2026.01.037_bib20","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1016\/j.ekir.2021.09.003","article-title":"The crystalline nephropathies","volume":"6","author":"Perazella","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.01.037_bib21","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.semnephrol.2010.09.005","article-title":"Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention\/therapy","volume":"30","author":"Perazella","year":"2010","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.kint.2026.01.037_bib22","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/mpo.10293","article-title":"Influence of high-dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function","volume":"40","author":"Hempel","year":"2003","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.kint.2026.01.037_bib23","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/01213011-200505000-00002","article-title":"A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination","volume":"15","author":"Hulot","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.kint.2026.01.037_bib24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s12185-021-03132-8","article-title":"Risk factors for high-dose methotrexate-induced nephrotoxicity","volume":"114","author":"Kawaguchi","year":"2021","journal-title":"Int J Hematol"},{"key":"10.1016\/j.kint.2026.01.037_bib25","doi-asserted-by":"crossref","first-page":"476","DOI":"10.34067\/KID.0000000725","article-title":"Prevention and treatment of acute kidney injury associated with high-dose methotrexate","volume":"6","author":"Faguer","year":"2025","journal-title":"Kidney360"},{"key":"10.1016\/j.kint.2026.01.037_bib26","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and managing toxicities of high-dose methotrexate","volume":"21","author":"Howard","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.kint.2026.01.037_bib27","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2009.25.4540","article-title":"Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome","volume":"28","author":"Widemann","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.kint.2026.01.037_bib28","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1182\/blood.2024026211","article-title":"Glucarpidase for treatment of high-dose methotrexate toxicity","volume":"145","author":"Gupta","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.kint.2026.01.037_bib29","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/S0272-6386(96)90384-4","article-title":"Effective clearance of methotrexate using high-flux hemodialysis membranes","volume":"28","author":"Wall","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.01.037_bib30","doi-asserted-by":"crossref","first-page":"602","DOI":"10.2215\/CJN.08030621","article-title":"Extracorporeal treatment for methotrexate poisoning: systematic review and recommendations from the EXTRIP workgroup","volume":"17","author":"Ghannoum","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.01.037_bib31","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.lungcan.2020.05.022","article-title":"Cumulative pemetrexed dose increases the risk of nephrotoxicity","volume":"146","author":"de Rouw","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.kint.2026.01.037_bib32","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00884-2018","article-title":"Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study","volume":"52","author":"Visser","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.kint.2026.01.037_bib33","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.bulcan.2014.12.012","article-title":"Pemetrexed nephrotoxicity","volume":"102","author":"Izzedine","year":"2015","journal-title":"Bull Cancer"},{"key":"10.1016\/j.kint.2026.01.037_bib34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.lungcan.2015.05.005","article-title":"Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world setting","volume":"89","author":"Sassier","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.kint.2026.01.037_bib35","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1053\/j.ajkd.2011.04.030","article-title":"Kidney tubular toxicity of maintenance pemetrexed therapy","volume":"58","author":"Glezerman","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.01.037_bib36","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1200\/JCO.2004.00.9720","article-title":"Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function","volume":"24","author":"Mita","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.kint.2026.01.037_bib37","first-page":"1116","article-title":"LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes","volume":"57","author":"Shih","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.kint.2026.01.037_bib38","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I","article-title":"The clinical pharmacology of methotrexate: new applications of an old drug","volume":"41","author":"Bleyer","year":"1978","journal-title":"Cancer"},{"key":"10.1016\/j.kint.2026.01.037_bib39","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/nep.14043","article-title":"Gemcitabine-induced renal thrombotic microangiopathy","volume":"27","author":"Horino","year":"2022","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.kint.2026.01.037_bib40","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/bcp.13808","article-title":"Thrombotic microangiopathy associated with gemcitabine use: presentation and outcome in a national French retrospective cohort","volume":"85","author":"Daviet","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.kint.2026.01.037_bib41","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1053\/j.ajkd.2015.02.340","article-title":"Thrombotic microangiopathy, cancer, and cancer drugs","volume":"66","author":"Izzedine","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.01.037_bib42","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s12882-021-02470-3","article-title":"Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre","volume":"22","author":"Grall","year":"2021","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2026.01.037_bib43","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1053\/j.ajkd.2025.06.014","article-title":"eculizumab prophylaxis for systematic rechallenging gemcitabine in gemcitabine-induced thrombotic microangiopathy: a case report","volume":"86","author":"Chewcharat","year":"2025","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.01.037_bib44","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/bmt.2014.186","article-title":"Not too little, not too much\u2014just right! (better ways to give high-dose melphalan)","volume":"49","author":"Shaw","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.kint.2026.01.037_bib45","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1046\/j.1523-1755.2003.00936.x","article-title":"Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosis","volume":"63","author":"Fadia","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.01.037_bib46","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1002\/cam4.2187","article-title":"Incidence and risk factors for acute kidney injury following autologous stem cell transplantation for multiple myeloma","volume":"8","author":"Andronesi","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.kint.2026.01.037_bib47","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7326\/0003-4819-140-2-200401200-00008","article-title":"High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8- year study","volume":"140","author":"Skinner","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2026.01.037_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fneph.2024.1436896","article-title":"Chemotherapy-induced acute kidney injury: epidemiology, pathophysiology, and therapeutic approaches","volume":"4","author":"Lyrio","year":"2024","journal-title":"Front Nephrol"},{"key":"10.1016\/j.kint.2026.01.037_bib49","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1053\/j.ajkd.2004.09.015","article-title":"Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation","volume":"45","author":"Leung","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.01.037_bib50","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s12185-018-2507-2","article-title":"Lower glomerular filtration rate predicts increased hepatic and mucosal toxicity in myeloma patients treated with high-dose melphalan","volume":"108","author":"Tamaki","year":"2018","journal-title":"Int J Hematol"},{"key":"10.1016\/j.kint.2026.01.037_bib51","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1054\/bjoc.2001.1928","article-title":"Glomerular filtration rate prior to high-dose melphalan 200 mg\/m2 as a surrogate marker of outcome in patients with myeloma","volume":"85","author":"Sirohi","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.kint.2026.01.037_bib52","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","article-title":"International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment","volume":"34","author":"Dimopoulos","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.kint.2026.01.037_bib53","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/bmt.2016.132","article-title":"Effect of severe hypoalbuminemia on toxicity of high-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis","volume":"51","author":"Lee","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.kint.2026.01.037_bib54","first-page":"11","article-title":"Mitomycin C nephrotoxicity","volume":"12","author":"Bennett","year":"1988","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.01.037_bib55","first-page":"1361","article-title":"Hemolytic-uremic syndrome associated with mitomycin C therapy","volume":"65","author":"Gordon","year":"1985","journal-title":"Blood"},{"key":"10.1016\/j.kint.2026.01.037_bib56","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0272-6386(86)80090-7","article-title":"Plasmapheresis and antiplatelet agents in the treatment of hemolytic uremic syndrome secondary to mitomycin","volume":"7","author":"Chow","year":"1986","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.01.037_bib57","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/1078155216628324","article-title":"Antineoplastic agents and thrombotic microangiopathy","volume":"23","author":"Garcia","year":"2017","journal-title":"J Oncol Pharm Pract"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826002231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826002231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T09:52:14Z","timestamp":1779270734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253826002231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0085253826002231"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2026.01.037","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Conventional cytotoxic chemotherapy\u2013associated nephrotoxicity: consensus report of the 34th Acute Disease Quality Initiative (ADQI) Workgroup","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.01.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society of Nephrology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}